Condition: Dilated Cardiomyopathy · Sponsor: Emory University
This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.
This description comes directly from the study's public registry record.
William Mahle, MD · 404-256-2593 · wmahle@emory.edu
Always discuss trial participation with your own doctor first.
| Grady Memorial Hospital | Atlanta, Georgia, United States | Recruiting |
| Hughes Spalding Children's Hospital | Atlanta, Georgia, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Arthur M. Blank Hospital | Atlanta, Georgia, United States | Recruiting |
| Scottish Rite Children's Hospital | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06464588